Monitoring of Antimicrobial Resistance Based on Metagenomics Analyses in Pneumonia Patients
NCT ID: NCT06566898
Last Updated: 2024-08-22
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
800 participants
OBSERVATIONAL
2024-08-01
2026-05-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
1. What is the microbiome maps of patients with severe pneumonia and mild pneumonia ?
2. How many pathogen resistance genes are carrying in severe pneumonia and mild pneumonia ?
3. What is the genetic diversity of key pathogens detected in severe pneumonia and mild pneumonia during 2019-2025?
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Microbiome and Host Susceptibility in Severe Pneumonia, a Prospective, Multicenter, Cohort Study
NCT06114784
The Association Mechanism Between the Microbiome and the Development of Community Pneumonia Was Studied Based on the Analysis of Pulmonary Microbiota - Host Interaction Network
NCT06896019
Chinese Hospital Acquired Pneumonia Collaboration Network: Epidemiology, Diagnosis and Treatment
NCT06028217
Second-generation Sequencing Guides the Treatment of Severe Pneumonia
NCT03884881
The Predictive Value of Molecular Diagnostic Techniques in the Antimicrobial- Resistance Phenotypes of Pathogens
NCT07035535
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Next-generation sequencing: Metagenomics and metatranscriptomic libraries undergo next-generation sequencing using the Illumina Novaseq 6000 platform.
Microbiome analysis: using KneadData (v0.10.0) reference from the human genome (GRCH38 reference database) to filter out the quality control of illumina sequencing data in Virosaurus download virus genome data sets for reference, bowtie2 (v2.3.4.1) (genome coverage \>30%, depth \>1X) was used to locate and analyze the post-host sequence, and then the "samtools idxstats" command was used to calculate the classification and relative abundance of viruses. Meanwhile, in order to obtain the annotation information of bacteria at the species level, PhyloFlash (v3.4) was used to calculate read counts for 16S rRNA genes in the SILVA database, selecting similarity greater than or equal to 98% as a threshold. Using eukaryotic pathogen genome database EUPATHDB46 as reference, bowtie2 and samtools were used for qualitative and quantitative analysis of fungal pathogens.
The criteria for determining the cause of respiratory infection are: (1) existing species known to be associated with human disease (ICD-10), (2) previously unidentified potential novel pathogens (only DNA and RNA viruses whose genera or families have previously been shown to infect mammals), and (3) possible symbiotic bacteria not included.
Analysis of AMR: by comparing the sequence similarity between the sequencing fragments and known drug resistance genes, the detection content can determine whether drug resistance genes exist, and suggest drug resistance caused by modification, inactivation, repression and other drug resistance genes.
Drug resistance genes detection: genes related to drug resistance recorded in CARD (Comprehensive Antibiotic Resistance Database) and ARG-ANNOT database. In this assay, only functional genes with drug resistance activities such as modification, inactivation, and repression, as well as pathway and target changes caused by some point mutations, were reported.
Genetic diversity was computed as the mean pairwise genetic distance within a group. Maximum likelihood phylogenetic trees were constructed using RaxML with a general time-reversible nucleotide substitution model and 1000 bootstraps. The genetic distance between sequences was calculated using MEGAX, with a bootstrap method for variance estimation.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Severe pneumonia
Patients clinically diagnosed as severe pneumonia are diagnosed according to the Guidelines for the diagnosis and Treatment of community-acquired pneumonia in Adults (2019 edition) formulated by the American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA), who meet 1 of the following major criteria or ≥3 minor criteria can be diagnosed. The diagnostic criteria for severe pneumonia in children were adopted by the British Thoracic Society (BTS) in 2011.
No interventions assigned to this group
Mild pneumonia
Patients clinically diagnosed as severe pneumonia and mild pneumonia are diagnosed according to the Guidelines for the diagnosis and Treatment of community-acquired pneumonia in Adults (2019 edition) formulated by the American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA). The diagnostic criteria for severe and mild pneumonia in children were adopted by the British Thoracic Society (BTS) in 2011
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Clinical examination was performed, and there was biospecimen (nasopharyngeal swab, oropharyngeal swab, bronchoalveolar lavage fluid, sputum, blood, hydrothorax, lung tissue) remaining in the clinical microbiological examination.
Exclusion Criteria
* Patients with alveolar lavage fluid or hydrothorax volume less than 200μl.
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wuxi People's Hospital Affiliated to Nanjing Medical University
UNKNOWN
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
OTHER
The Central Hospital of Huanggang
OTHER
Shanghai General Hospital, China
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Mei Kang
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mei Kang, MPH
Role: PRINCIPAL_INVESTIGATOR
Shanghai General Hospital, Shanghai Jiaotong University School of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mei Kang
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020 Oct 17;396(10258):1204-1222. doi: 10.1016/S0140-6736(20)30925-9.
File TM Jr, Ramirez JA. Community-Acquired Pneumonia. N Engl J Med. 2023 Aug 17;389(7):632-641. doi: 10.1056/NEJMcp2303286. No abstract available.
Limmathurotsakul D, Dunachie S, Fukuda K, Feasey NA, Okeke IN, Holmes AH, Moore CE, Dolecek C, van Doorn HR, Shetty N, Lopez AD, Peacock SJ; Surveillance and Epidemiology of Drug Resistant Infections Consortium (SEDRIC). Improving the estimation of the global burden of antimicrobial resistant infections. Lancet Infect Dis. 2019 Nov;19(11):e392-e398. doi: 10.1016/S1473-3099(19)30276-2. Epub 2019 Aug 16.
Park DE, Higdon MM, Prosperi C, Baggett HC, Brooks WA, Feikin DR, Hammitt LL, Howie SRC, Kotloff KL, Levine OS, Madhi SA, Murdoch DR, O'Brien KL, Scott JAG, Thea DM, Antonio M, Awori JO, Baillie VL, Bunthi C, Kwenda G, Mackenzie GA, Moore DP, Morpeth SC, Mwananyanda L, Paveenkittiporn W, Ziaur Rahman M, Rahman M, Rhodes J, Sow SO, Tapia MD, Deloria Knoll M. Upper Respiratory Tract Co-detection of Human Endemic Coronaviruses and High-density Pneumococcus Associated With Increased Severity Among HIV-Uninfected Children Under 5 Years Old in the PERCH Study. Pediatr Infect Dis J. 2021 Jun 1;40(6):503-512. doi: 10.1097/INF.0000000000003139.
Chiu CY, Miller SA. Clinical metagenomics. Nat Rev Genet. 2019 Jun;20(6):341-355. doi: 10.1038/s41576-019-0113-7.
Li N, Cai Q, Miao Q, Song Z, Fang Y, Hu B. High-Throughput Metagenomics for Identification of Pathogens in the Clinical Settings. Small Methods. 2021 Jan 4;5(1):2000792. doi: 10.1002/smtd.202000792. Epub 2020 Dec 13.
Zhang YZ, Chen YM, Wang W, Qin XC, Holmes EC. Expanding the RNA Virosphere by Unbiased Metagenomics. Annu Rev Virol. 2019 Sep 29;6(1):119-139. doi: 10.1146/annurev-virology-092818-015851. Epub 2019 May 17.
Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, Hu Y, Tao ZW, Tian JH, Pei YY, Yuan ML, Zhang YL, Dai FH, Liu Y, Wang QM, Zheng JJ, Xu L, Holmes EC, Zhang YZ. A new coronavirus associated with human respiratory disease in China. Nature. 2020 Mar;579(7798):265-269. doi: 10.1038/s41586-020-2008-3. Epub 2020 Feb 3.
Boolchandani M, D'Souza AW, Dantas G. Sequencing-based methods and resources to study antimicrobial resistance. Nat Rev Genet. 2019 Jun;20(6):356-370. doi: 10.1038/s41576-019-0108-4.
Suzuki S, Horinouchi T, Furusawa C. Prediction of antibiotic resistance by gene expression profiles. Nat Commun. 2014 Dec 17;5:5792. doi: 10.1038/ncomms6792.
Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022 Feb 12;399(10325):629-655. doi: 10.1016/S0140-6736(21)02724-0. Epub 2022 Jan 19.
Howard A, Reza N, Aston S, Woods B, Gerada A, Buchan I, Hope W, Martson AG. Antimicrobial treatment imprecision: an outcome-based model to close the data-to-action loop. Lancet Infect Dis. 2024 Jan;24(1):e47-e58. doi: 10.1016/S1473-3099(23)00367-5. Epub 2023 Aug 31.
Serpa PH, Deng X, Abdelghany M, Crawford E, Malcolm K, Caldera S, Fung M, McGeever A, Kalantar KL, Lyden A, Ghale R, Deiss T, Neff N, Miller SA, Doernberg SB, Chiu CY, DeRisi JL, Calfee CS, Langelier CR. Metagenomic prediction of antimicrobial resistance in critically ill patients with lower respiratory tract infections. Genome Med. 2022 Jul 12;14(1):74. doi: 10.1186/s13073-022-01072-4.
Shi M, Zhao S, Yu B, Wu WC, Hu Y, Tian JH, Yin W, Ni F, Hu HL, Geng S, Tan L, Peng Y, Song ZG, Wang W, Chen YM, Holmes EC, Zhang YZ. Total infectome characterization of respiratory infections in pre-COVID-19 Wuhan, China. PLoS Pathog. 2022 Feb 17;18(2):e1010259. doi: 10.1371/journal.ppat.1010259. eCollection 2022 Feb.
Charalampous T, Alcolea-Medina A, Snell LB, Williams TGS, Batra R, Alder C, Telatin A, Camporota L, Meadows CIS, Wyncoll D, Barrett NA, Hemsley CJ, Bryan L, Newsholme W, Boyd SE, Green A, Mahadeva U, Patel A, Cliff PR, Page AJ, O'Grady J, Edgeworth JD. Evaluating the potential for respiratory metagenomics to improve treatment of secondary infection and detection of nosocomial transmission on expanded COVID-19 intensive care units. Genome Med. 2021 Nov 17;13(1):182. doi: 10.1186/s13073-021-00991-y.
Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, Cooley LA, Dean NC, Fine MJ, Flanders SA, Griffin MR, Metersky ML, Musher DM, Restrepo MI, Whitney CG. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45-e67. doi: 10.1164/rccm.201908-1581ST.
Harris M, Clark J, Coote N, Fletcher P, Harnden A, McKean M, Thomson A; British Thoracic Society Standards of Care Committee. British Thoracic Society guidelines for the management of community acquired pneumonia in children: update 2011. Thorax. 2011 Oct;66 Suppl 2:ii1-23. doi: 10.1136/thoraxjnl-2011-200598.
Li ZJ, Zhang HY, Ren LL, Lu QB, Ren X, Zhang CH, Wang YF, Lin SH, Zhang XA, Li J, Zhao SW, Yi ZG, Chen X, Yang ZS, Meng L, Wang XH, Liu YL, Wang X, Cui AL, Lai SJ, Jiang T, Yuan Y, Shi LS, Liu MY, Zhu YL, Zhang AR, Zhang ZJ, Yang Y, Ward MP, Feng LZ, Jing HQ, Huang LY, Xu WB, Chen Y, Wu JG, Yuan ZH, Li MF, Wang Y, Wang LP, Fang LQ, Liu W, Hay SI, Gao GF, Yang WZ; Chinese Centers for Disease Control and Prevention (CDC) Etiology of Respiratory Infection Surveillance Study Team. Etiological and epidemiological features of acute respiratory infections in China. Nat Commun. 2021 Aug 18;12(1):5026. doi: 10.1038/s41467-021-25120-6.
Alcock BP, Raphenya AR, Lau TTY, Tsang KK, Bouchard M, Edalatmand A, Huynh W, Nguyen AV, Cheng AA, Liu S, Min SY, Miroshnichenko A, Tran HK, Werfalli RE, Nasir JA, Oloni M, Speicher DJ, Florescu A, Singh B, Faltyn M, Hernandez-Koutoucheva A, Sharma AN, Bordeleau E, Pawlowski AC, Zubyk HL, Dooley D, Griffiths E, Maguire F, Winsor GL, Beiko RG, Brinkman FSL, Hsiao WWL, Domselaar GV, McArthur AG. CARD 2020: antibiotic resistome surveillance with the comprehensive antibiotic resistance database. Nucleic Acids Res. 2020 Jan 8;48(D1):D517-D525. doi: 10.1093/nar/gkz935.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023234
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.